Daily Bio News Summary — 2026-09-15: FDA Launches TrialBlazer as GSK, Novo, and Lilly Drive a Packed Deal and Pipeline Day

The September 15 harvest captured 36 articles across eight sources — BioSpace, Endpoints News, Fierce Biotech, Fierce Pharma, BioPharma Dive, Pharmaphorum, PR Newswire, and FDA Newsroom — plus MedCity News and STAT News. The day was dominated by FDA regulatory activity, mega-pharma pipeline setbacks, and a steady drumbeat of dealmaking.

FDA Launches Operation TrialBlazer

The FDA was the day’s busiest institution. The agency formally launched Operation TrialBlazer, an expedited IND pilot program designed to partner drugmakers with research institutions to accelerate first-in-human development in the United States. The initial application window closes October 30, 2026 (FDA Newsroom, 2026-09-15; BioSpace, 2026-09-15; BioPharma Dive, 2026-09-15; Endpoints News, 2026-09-15). FDA leaders told Endpoints they have “woven in feedback” from industry stakeholders as the program goes live, signaling a collaborative posture from the agency.

The FDA also approved the first radioligand equivalent — Curium’s copycat of Novartis’ Lutathera — marking a regulatory milestone for the radiopharmaceutical market (Fierce Pharma, 2026-09-15). Separately, the agency set a Q1 decision date for Takeda’s psoriasis blockbuster hope zasocitinib (Pharmaphorum, 2026-09-15), adding another near-term catalyst to the TYK2 inhibitor race.

Psychedelic regulation drew fresh attention: stakeholders urged the FDA to define data and treatment standards as psychedelic therapies near market (BioSpace, 2026-09-15), while experts called for provider credentialing requirements (Endpoints News, 2026-09-15).

GSK: $750M Chimagen Deal and Factory Closure

GSK dominated the deal headlines with a $750M pact for Chimagen Biosciences’ trispecific T-cell engager targeting multiple myeloma (Endpoints News, 2026-09-15; BioSpace, 2026-09-15; Fierce Biotech, 2026-09-15; Pharmaphorum, 2026-09-15). The four-source coverage underscores the significance: trispecific engagers are an emerging modality, and GSK is betting big on Chimagen’s differentiated approach.

The same day, GSK announced it will wind down its German vaccine manufacturing site, laying off 650 staffers due to lack of demand for its flu vaccine (Endpoints News, 2026-09-15; BioSpace, 2026-09-15). The move signals continued restructuring under GSK’s portfolio-optimization strategy.

Novo Nordisk: Rebrand and Pipeline Trim

Novo Nordisk dropped the “Nordisk” moniker in a major corporate rebrand (BioSpace, 2026-09-14; Fierce Pharma, 2026-09-14), shortening its name as part of a broader brand and cultural overhaul. The same day, Fierce Biotech reported that Novo scrapped a $285M pact with Ascendis Pharma to develop a monthly GLP-1 weight-loss drug (Fierce Biotech, 2026-09-15). The Ascendis termination is notable given the obesity field’s competitive intensity — Novo appears to be consolidating its internal GLP-1 pipeline rather than relying on external partnerships.

Lilly Doubles Down on CNS With $237M Gene-Therapy Collab

Eli Lilly announced a new collaboration paying up to $237M per program in CNS genetic medicine (Fierce Biotech, 2026-09-15). The deal signals Lilly’s growing ambition beyond its GLP-1 franchise and into neurological disease — a space where gene therapy is gaining traction as a potential one-time treatment modality.

Pipeline Setbacks: AstraZeneca, J&J-Contineum, Axoltis

Several Phase 2 and Phase 3 failures made headlines:

• AstraZeneca’s newly approved breast cancer pill (etcamah) failed a frontline study — the second oral SERD to fall short in first-line breast cancer (BioSpace, 2026-09-14; BioPharma Dive, 2026-09-15). This is a significant setback for AZ’s oncology ambitions despite the drug’s recent FDA approval.
• J&J-Contineum depression drug flunked another Phase 2 test (Fierce Biotech, 2026-09-15; Endpoints News, 2026-09-15), continuing a string of failures for the PIPE inhibitor class in depression.
• Axoltis’ ALS drug Phase 2 study failed (Endpoints News, 2026-09-15), adding to the long list of ALS clinical disappointments.
• Connect Biopharma saw its Dupixent rival miss its primary asthma endpoint, though the company says it is not dismayed (Fierce Biotech, 2026-09-15).

Not all was negative: Cullinan-Taiho plans to proceed with an FDA filing for its lung cancer pill despite three patient deaths, citing survival benefit (BioSpace, 2026-09-15).

Positive Clinical and Regulatory Signals

Scholar Rock won first-in-class FDA approval for Isembyld in spinal muscular atrophy — a significant milestone for the SMA field (MedCity News, 2026-09-15). Vera’s Trutakna showed strong Phase 3 results in IgA nephropathy, eyeing full approval (Endpoints News, 2026-09-15). Nuvation Bio reinforced IBTROZI’s efficacy in ROS1+ non-small cell lung cancer with new analyses at the 2026 World Conference on Lung Cancer (PR Newswire, 2026-09-15). And Summit/Akeso looked to shed doubts about their PD-1/VEGF drug with latest study results (BioPharma Dive, 2026-09-15).

Financing, M&A, and Leadership

The deal and capital markets remained active:

• RegCell raised $66M to advance Nobel-winning Treg therapies into the clinic (Endpoints News, 2026-09-15) — a notable signal for the regulatory T-cell space.
• Electra Therapeutics set IPO terms hoping to raise up to $347M (Pharmaphorum, 2026-09-15), keeping the biotech IPO window open.
• Cheplapharm agreed to take over 20 older medicines from Sanofi (Fierce Pharma, 2026-09-15), continuing Sanofi’s portfolio rationalization under new CEO direction.
• Cellectis quit its allogeneic CAR-T programs entirely to pivot toward in vivo gene editing (BioPharma Dive, 2026-09-15) — a dramatic strategic shift.
• CereVasc appointed Tony Kingsley as new President and CEO (PR Newswire, 2026-09-15).
• Chiesi filled its permanent CEO role with Flagship’s Khougazian (Pharmaphorum, 2026-09-15).
• Kairon Health raised $5M to use data to make patients healthier (Endpoints News, 2026-09-15).

Industry Trends and Regulatory Policy

Rare disease reform, CMC risk, and reshoring US trials are top of mind ahead of the PDUFA VIII meeting (BioSpace, 2026-09-15). Applied Photonix launched ViroZap, the first FDA-cleared medical device for in-duct air disinfection (PR Newswire, 2026-09-15). And a STAT News feature covered how exercise and echocardiograms in space protected astronauts’ hearts (STAT News, 2026-09-15).

What This Batch Is NOT Telling Us

Today’s harvest is notably thin on AI-in-bio, gene therapy clinical readouts, and IPO aftermarket performance. The psychedelic regulation stories hint at a growing policy conversation but no approvals yet. China biotech activity is present (Chimagen deal, Summit/Akeso WCLC data) but not the dominant theme. There is no major M&A announcement beyond the Cheplapharm/Sanofi divestiture.

Reading Order

For readers with limited time, the highest-signal items today are:

1. FDA Operation TrialBlazer — the most consequential regulatory story of the day
2. GSK/Chimagen $750M deal — signals continued interest in trispecific T-cell engagers
3. Novo rebrand + Ascendis pact scrap — a pivot moment for the obesity leader
4. Scholar Rock SMA approval — first-in-class is always worth noting
5. Lilly $237M CNS gene-therapy collab — big pharma moving beyond GLP-1
6. AstraZeneca breast cancer pill failure — another oral SERD stumbles in frontline

---

Complete Article List (2026-09-15)

1. FDA opens Operation TrialBlazer for applications — BioSpace, 2026-09-15
2. FDA launches expedited IND pilot, begins accepting applications — FDA Newsroom, 2026-09-15
3. FDA launches pilot program to speed up early US drug research — BioPharma Dive, 2026-09-15
4. FDA leaders say they’ve woven in feedback as expedited trial program goes live — Endpoints News, 2026-09-15
5. FDA approves first radioligand equivalent — Fierce Pharma, 2026-09-15
6. FDA to decide on Takeda’s psoriasis blockbuster hope in Q1 — Pharmaphorum, 2026-09-15
7. GSK bags Chimagen’s trispecific T-cell engager in deal worth up to $750M — BioSpace, 2026-09-15
8. GSK doubles down on Chimagen with $750M multiple myeloma wager — Fierce Biotech, 2026-09-15
9. GSK strikes deal for Chimagen’s T-cell engager for blood cancer — Endpoints News, 2026-09-15
10. GSK wagers $750M on Chimagen multiple myeloma therapy — Pharmaphorum, 2026-09-15
11. GSK lays off 650 staffers amid closure of German vaccine manufacturing site — BioSpace, 2026-09-15
12. GSK to wind down German vaccine factory due to lack of demand — Endpoints News, 2026-09-15
13. Novo scraps $285M pact with Ascendis to develop monthly GLP-1 — Fierce Biotech, 2026-09-15
14. Lilly pledges up to $237M per program in CNS genetic med collab — Fierce Biotech, 2026-09-15
15. J&J-Contineum depression drug flunks another ph. 2 test — Fierce Biotech, 2026-09-15
16. Contineum, J&J’s drug fails in mid-stage depression trial — Endpoints News, 2026-09-15
17. AstraZeneca’s newly approved pill fails frontline breast cancer study — BioPharma Dive, 2026-09-15
18. Axoltis says its Phase 2 study for an experimental ALS drug failed — Endpoints News, 2026-09-15
19. Connect not dismayed by Dupixent rival’s ph. 2 asthma failure — Fierce Biotech, 2026-09-15
20. Scholar Rock Drug Wins First-in-Class Approval in Rare Neuromuscular Disease — MedCity News, 2026-09-15
21. Vera eyes full approval for Trutakna in IgAN following positive readout — Endpoints News, 2026-09-15
22. Nuvation Bio Announces New Analyses Reinforcing IBTROZI Efficacy at WCLC — PR Newswire, 2026-09-15
23. Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results — BioPharma Dive, 2026-09-15
24. Exclusive: RegCell gets $66M boost to take Nobel-winning Tregs into clinic — Endpoints News, 2026-09-15
25. Electra sets terms for IPO, hoping to raise up to $347M — Pharmaphorum, 2026-09-15
26. Cheplapharm to take over 20 medicines from Sanofi — Fierce Pharma, 2026-09-15
27. Cellectis quits CAR-T and pivots to in vivo gene editing — BioPharma Dive, 2026-09-15
28. CereVasc Appoints Tony Kingsley as President and CEO — PR Newswire, 2026-09-15
29. Chiesi fills permanent CEO role with Flagship’s Khougazian — Pharmaphorum, 2026-09-15
30. Exclusive: Kairon Health raises $5M to use data to make patients healthier — Endpoints News, 2026-09-15
31. Stakeholders urge FDA to define data, treatment standards as psychedelic drugs near market — BioSpace, 2026-09-15
32. FDA should require credentials for psychedelic providers, experts say — Endpoints News, 2026-09-15
33. Rare disease reform, CMC risk, reshoring US trials top of mind ahead of PDUFA VIII — BioSpace, 2026-09-15
34. Despite 3 patient deaths, Cullinan-Taiho plan FDA filing for lung cancer pill — BioSpace, 2026-09-15
35. Applied Photonix Launches ViroZap, the First FDA-Cleared Medical Device for In-Duct Air Disinfection — PR Newswire, 2026-09-15
36. Exercise and echocardiograms in space protected astronauts’ hearts in study — STAT News, 2026-09-15